Willies Wu is a digital health and medtech leader with deep expertise in managing the full software/system development life cycle (SDLC) within FDA-regulated environments. With extensive experience in biotech and medical device innovation, he specializes in building compliant, high-quality health software for the U.S. and international markets.

At Foresight Diagnostics, Willies leads the development and deployment of digital health solutions that meet stringent regulatory standards while addressing critical healthcare needs. His work sits at the intersection of engineering execution, regulatory strategy, and product innovation — ensuring that software-driven medical technologies move efficiently from concept to compliant commercialization.

With a strong foundation in quality systems and global regulatory frameworks, he brings both technical rigor and strategic oversight to highly regulated, fast-evolving healthcare environments.

Willies is particularly well-suited to mentor individuals interested in digital health innovation, regulatory strategy, and leading product development within highly regulated medical technology environments.

Dr. Ryan Smith is a patent attorney with deep scientific roots and extensive experience protecting high-value biotechnology and chemical innovations. With a Ph.D. in Chemistry from UC Berkeley and prior research roles at Illumina and GE Healthcare, Dr. Smith combines cutting-edge scientific expertise with strategic intellectual property execution.

Dr. Smith practices across U.S. and international patent prosecution in biotechnology and chemical arts, including bioanalytical methods such as mass spectrometry, ELISA, DNA sequencing, and PCR. His work spans non-infringement and invalidity analyses, freedom-to-operate strategy, and IP due diligence for mergers and acquisitions, public offerings, and private equity investments.

He has crafted and prosecuted intellectual property portfolios protecting multimillion-dollar therapeutics, including Solosec® and Xiflam™, and has led worldwide patent strategies securing regulatory exclusivity advantages. His prosecution of a fluorescent protein patent for Allele Biotechnology played a key role in enforcement efforts related to Covid-19 vaccine development. Notably, his scientific contributions at Illumina were cited by the 2022 Nobel Committee in awarding the Nobel Prize in Chemistry.

Dr. Smith works with entrepreneurs, emerging growth companies, university technology transfer offices, and global pharmaceutical companies to build comprehensive, defensible IP portfolios that support long-term innovation and enterprise value.

Dr. Smith is particularly well-suited to mentor scientists and entrepreneurs who seek to understand how intellectual property drives valuation, protects innovation, and shapes the strategic future of biotechnology enterprises.

Dr. Chun-Pyn Shen is a seasoned biotech and pharmaceutical consultant whose career spans academia, industry, and multiple major professional transitions across four decades. His journey reflects resilience, adaptability, and strategic reinvention in an ever-evolving life sciences landscape.

His professional path includes: a Dentistry track at National Taiwan University (1981–1989); an Academic track with a PhD in Molecular Biology from the University of Pennsylvania and postdoctoral training in neuroscience and Drosophila genetics at UCSF (1989–1998); and a Biopharma & Consulting track (1998–present) spanning Merck & Co., AdaptImmune, Questcor/Mallinckrodt Pharmaceuticals, EMD Serono, Henlius Biotech, DynamiCure Biotechnology, Impact Therapeutics, and independent consulting.

Across his industry career, Dr. Shen has navigated multiple organizational restructurings and four layoffs — emerging each time with renewed direction and strategic growth. His experience provides rare insight into career resilience, reinvention, and long-term professional sustainability in biotech.

Dr. Shen is particularly well-suited to mentor individuals seeking guidance on career resilience, cross-sector transitions, and building sustainable long-term success in biotech and pharmaceutical industries.

Dr. Robert Lou brings deep scientific expertise in cell and developmental biology, with a research focus on RNA metabolism and neural development. His academic foundation provides a strong understanding of fundamental biological mechanisms that underpin next-generation therapeutic innovation.

In industry, Dr. Lou has extensive experience in the Cell and Gene Therapy (CGT) field, spanning R&D, process development, and GMP manufacturing. His work bridges early-stage discovery with scalable production — translating complex biology into clinically viable and commercially scalable therapeutic platforms.

With exposure to startup environments and venture investing perspectives, Dr. Lou offers insight into how scientific innovation is evaluated, developed, and positioned for long-term growth within competitive biotech ecosystems.

Dr. Lou is particularly well-suited to mentor individuals interested in advanced therapeutics, translational science, and navigating the interface between research innovation, industrial scale-up, and venture strategy.

James Chu is a senior pharmaceutical development leader with over 35 years of experience in CMC, formulation, and parenteral drug technologies. His expertise spans lipid nanoparticles (RNA-LNP), liposomal systems, nano-emulsions, suspension formulations, and lyophilization technologies — supporting programs from early discovery through cGMP manufacturing and regulatory submission.

Currently serving as Director of Pharmaceutical R&D at Nitto BioPharma, James leads LNP drug product and process optimization across bench, pilot, and CDMO manufacturing stages. His work integrates Quality by Design (QbD), Design of Experiments (DoE), and predictive modeling to identify critical quality attributes (CQA) and critical process parameters (CPP), enabling scalable and regulatory-ready development strategies.

Over the course of his career — including leadership roles at Pfizer Global R&D, Nereus Pharmaceuticals, and Latitude Pharmaceuticals — James has successfully developed and transferred multiple sterile and nanoparticle-based drug products into clinical and GMP production environments. He has co-authored CMC sections for IND and NDA submissions and contributed to multiple issued U.S. patents.

Beyond technical leadership, James is deeply committed to mentoring and team development, helping scientists strengthen problem-solving frameworks, decision-making skills, and long-term career positioning within pharmaceutical development.

James is particularly well-suited to mentor individuals interested in the technical and regulatory backbone of pharmaceutical development, especially in advanced delivery systems and scalable CMC strategy.

Howard Lei is an accomplished executive with over 20 years of experience across the United States and China, leading strategic initiatives for Fortune 500 organizations and high-growth healthcare companies. His work focuses on improving operational efficiency, driving business transformation, and shaping long-term competitive strategy within complex healthcare markets.

Specializing in healthcare strategy, Howard has led major engagements spanning strategic planning, business development, and business innovation. He brings a global perspective on how healthcare systems operate, how capital flows influence innovation, and how organizations position themselves for sustainable growth in regulated and competitive environments.

With experience in venture investing and startup ecosystems, he offers insight into both corporate-level decision-making and entrepreneurial execution.

Howard is particularly well-suited to mentor individuals interested in healthcare strategy, corporate development, venture investing, and leadership roles that require a deep understanding of both market dynamics and organizational transformation.

Dr. Chen is a physician-scientist and entrepreneur with an MD–PhD background in pathology and medical genetics. As a CLIA-certified laboratory director, he brings deep expertise at the intersection of clinical diagnostics, translational medicine, and biotech innovation.

With extensive experience spanning clinical development, business development, and startup leadership, Dr. Chen has navigated both the scientific and strategic sides of the biotech and pharmaceutical industries. His career bridges bench-to-bedside translational research, regulatory laboratory operations, and the realities of building and scaling ventures in highly regulated healthcare environments.

Dr. Chen is particularly well-suited to mentor individuals interested in physician-scientist careers, biotech entrepreneurship, and leadership roles that require both scientific depth and business acumen.

Emily Chen is a proteomics and precision medicine leader who transforms scientific breakthroughs into real-world impact. With deep expertise in biomarker discovery and oncology, she operates at the intersection of complex science, strategic execution, and commercialization.

Her career reflects a strong “T-shaped” profile — combining advanced technical depth in proteomics and translational research with cross-functional leadership spanning product development, operations, and business strategy. Emily has successfully bridged academia and industry, contributing to NIH-funded initiatives while driving innovation in highly regulated and competitive markets.

From early-stage discovery to new product introductions (NPI), she excels at aligning R&D, business strategy, and marketing to move innovations from concept to market. Equipped with an MBA and PMP certification, she brings disciplined strategic decision-making and operational clarity to scientific leadership.

Emily is particularly well-suited to mentor individuals seeking to bridge science and strategy, transition into biotech leadership roles, or build careers that combine deep technical expertise with business impact.

Sherida Johnson is a respected, results-driven scientist and business leader with extensive experience managing large-scale research initiatives and translating scientific excellence into product and commercial impact.

Throughout her R&D career, Sherida has led high-performance laboratory teams, ensuring regulatory compliance, operational efficiency, and the successful development of innovative methodologies. She is known for balancing scientific rigor with strategic risk management to meet ambitious program objectives.

Transitioning into Business Development within the pharmaceutical industry, Sherida has spearheaded regional growth initiatives — building strong client partnerships, aligning scientific programs with business goals, and driving measurable revenue expansion. Her ability to communicate complex scientific concepts clearly — both internally and externally — has enabled successful collaboration across investigators, vendors, and executive stakeholders.

Her career exemplifies the evolution from technical scientific leadership to strategic commercial influence.

Sherida is particularly well-suited to mentor individuals seeking to expand beyond the laboratory into leadership and commercial-facing roles while maintaining strong scientific credibility.

Allen Lin is a fluidics engineer specializing in medical device platform development across point-of-care testing (POCT), digital PCR (dPCR), and next-generation sequencing (NGS) technologies. His work focuses on building the engineering foundations that enable advanced diagnostic systems to function reliably, accurately, and at scale.

With expertise in microfluidics and system integration, Allen contributes to the development of next-generation diagnostic platforms that bridge engineering precision with clinical application. His experience spans both academic research and startup environments, offering insight into how innovative device concepts evolve into deployable healthcare solutions.

Operating at the interface of engineering design and translational application, he brings a strong understanding of how platform technologies shape the future of molecular diagnostics and precision medicine.

Allen is particularly well-suited to mentor individuals interested in medtech innovation, platform engineering, and building the technical backbone of next-generation diagnostic technologies.